Arrhythmogenic cardiomyopathy (AC) is a rare inherited heart muscle condition that causes irregular heart rhythms (arrhythmias) at a higher rate than other heart muscle conditions. AC can affect primarily either the left ventricle (Left Dominant Arrhythmogenic Cardiomyopathy) or the right ventricle (Arrhythmogenic Right Ventricular Cardiomyopathy or ARVC). Individuals with AC or ARVC may have symptoms of palpitations or fainting due to arrhythmias. Symptoms may also include shortness of breath due to reduced pumping function of the heart.
Medical Services related to Supriya Shore MBBS
During the first 30 days following discharge, heart failure patients face a critical time in their recovery. The Inpatient Heart Failure Service has been developed to provide heart failure patients with all of the resources they need for success and to minimize the chance for readmission. Having close monitoring and support, as well as education about their health process is key to an optimal outcome.
Dilated cardiomyopathy, or DCM, is a heart muscle condition characterized by gradual weakening of the heart muscle. While DCM may be caused by other conditions, including myocardial infarction, many cases are now known to be caused by genetic mutations carried in families. Individuals with DCM may be only mildly affected or may be severely affected, even in the same family.
The University of Michigan offers the state's only accredited heart failure disease management program, with medical and surgical care, heart-assisting technology and comprehensive rehabilitation programs.
Heart transplant is one of a number of options for severe heart disease. It's not for everyone, and should not be considered unless all other viable treatment options have been unsuccessful. At the University of Michigan Heart Transplant Program, our closely integrated team of cardiac transplant surgeons and transplant cardiologists are able to treat and implant donor hearts in the sickest of patients because of our high volume, vast experience and active research program.
Hypertrophic cardiomyopathy (HCM) is a common genetic cardiac disorder affecting 1 in 500 people. It affects both men and women of all ages, and is characterized by abnormal thickening of the heart muscle.
VADs (ventricular assist devices) are mechanical devices that help your heart pump blood to the rest of your body when other methods don't relieve heart failure symptoms. LVADs, the most common type of VAD, are used to support the left side of the heart, but RVADs may be used to support the right side of the heart as well. The University of Michigan Frankel Cardiovascular Center is home to one of the largest VAD programs in the country, and is one of only a few institutions worldwide that has access to many investigational and FDA-approved mechanical circulatory support devices.
The VAD Program at the University of Michigan offers one of the nation's most comprehensive programs in the area of treatment for severe chronic or acute heart failure. This goes beyond conventional treatment, giving patients access to a broad variety of state-of-the-art options of circulatory support devices and skilled post-implantation care.